Diligence memo · auto-generated · as of July 2, 2026

Enquyst Technologies Inc.

Enquyst Technologies Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Enquyst Technologies Inc. operates in Biotechnology, based in LOWELL.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Enquyst Technologies Inc. has raised $6.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.0M on 2025-06-04.

Most recent recorded round closed around 2025-06-04.

Valuation (modeled)modeled

Provath models Enquyst Technologies Inc. at approximately $20M (range $6.5M–$35M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.29× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 13 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 47% of Biotechnology peers (4293 compared).

Modeled value ranks above 29% of those peers.

Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.